Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy

What Was Tested

This randomized controlled trial paper looks at Insulin Lispro.

To compare health-related quality of life (HRQOL) in patients with diabetes receiving insulin lispro with patients receiving regular human insulin (Humulin R).

Who Took Part

According to the abstract, 468 patients were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

The researchers performed two randomized comparative studies over a 6-month period (3 months per treatment).

One HRQOL crossover study included 468 patients with type I diabetes; the other HRQOL crossover study included 474 patients with type II diabetes.

How the Study Was Run

The design is described as randomized and crossover.

Because people in this Insulin Lispro study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Each person switched between Insulin Lispro and the comparison at some point, usually with a gap in between.

The timeline in the abstract includes 6 months.

Primary analyses used crossover baseline to 3-month changes in HRQOL scores.

Ninety-three principal investigators in Canada, France, Germany, and the U.S. participated in these studies.

In both studies, patients were taking insulin at least 2 months before enrollment.

Primary outcomes included two generic HRQOL domains, energy/fatigue and health distress, and two diabetes-specific domains, treatment satisfaction and treatment flexibility.

Thirty secondary outcomes included both generic and diabetes-specific measures.

What Was Measured

Secondary outcome domains were controlled for multiplicity in the analyses.

The subject headings attached to it are Demography, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Health Status, Hypoglycemic Agents, Insulin and Insulin Lispro.

What This Means in Plain Language

The paper is a randomized and crossover study of Insulin Lispro in 468 patients over 6 months.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1997 (Diabetes care), a journal based in United States.

More context: the Insulin Lispro compound page, all human trials.